Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).
27-10-2018 | Denosumab | ACR/ARHP 2018 | Video
Browse topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings
Conferences